RekrutujeFaza III
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib…
Miasta: Bydgoszcz, Gliwice, Katowice, Toruń i 2 inne miastaWiek: od 18 latSponsor: University Of Cologne
RekrutujeFaza III
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Miasta: Bydgoszcz, Poznań, WarszawaWiek: od 18 latSponsor: Ferring Pharmaceuticals A/S
RekrutujeFaza II
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With…
Miasta: Gdańsk, Katowice, Kraków, Nowy Sącz i 3 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza IV
Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
Miasta: Gdańsk, Kraków, WarszawaWiek: od 18 latSponsor: Replimune Group Inc.
RekrutujeFaza I/II
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically…
Miasta: Brzozów, Koszalin, Kraków, Otwock i 1 inne miastoWiek: od 18 latSponsor: Glaxosmithkline Research & Development Limited
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza I/II
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC)…
Miasta: Gdańsk, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Miasta: Gliwice, WarszawaWiek: od 18 latSponsor: Novartis Pharma AG
RekrutujeFaza II
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Miasta: Chorzów, Katowice, WarszawaWiek: od 18 latSponsor: Glaxosmithkline Research & Development Limited
RekrutujeFaza III
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer…
Miasta: Białystok, Bydgoszcz, Gdynia, Koszalin i 6 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza II
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Miasta: Poznań, Tarnów, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent…
Miasta: Białystok, Gdańsk, Kielce, Poznań i 2 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza I/II
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Miasta: Koszalin, Kraków, Poznań, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Miasta: Poznań, Rzeszów, Siedlce, Stupsk i 3 inne miastaWiek: od 18 latSponsor: Gilead Sciences Inc.
RekrutujeFaza I/II
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Miasta: Białystok, Gliwice, Józefów, WarszawaWiek: od 18 latSponsor: Glaxosmithkline Research & Development Limited i jeszcze 1
RekrutujeFaza I
Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies
Miasta: Gdańsk, Kraków, Warszawa, ŁódźWiek: od 18 latSponsor: Adamed Pharma S.A.
W Polsce: Rekrutacja wstrzymanaNa świecie: RekrutujeFaza III
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously…
Miasta: Bystra, Gdańsk, Kraków, Lublin i 7 innych miastWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza III
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive…
Miasta: Białystok, Konin, Koszalin, Kraków i 7 innych miastWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
W Polsce: ZakończoneNa świecie: RekrutujeFaza I
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Miasta: Białystok, Gdańsk, Otwock, Siedlce i 1 inne miastoWiek: od 18 latSponsor: Nextcure Inc.
RekrutujeFaza II/III
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Miasta: Białystok, Katowice, Olsztyn, Poznań i 3 inne miastaWiek: od 18 latSponsor: Moleculin Biotech Inc.
RekrutujeFaza II/III
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Miasta: Bydgoszcz, Gdańsk, Gliwice, Katowice i 4 inne miastaWiek: od 18 latSponsor: Bicara Therapeutics Inc.
RekrutujeFaza III
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Miasta: Gdańsk, Gliwice, Kraków, Poznań i 1 inne miastoWiek: od 0 latSponsor: Novartis Pharma AG
RekrutujeFaza II
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Miasta: Gdańsk, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza II
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Miasta: Gdańsk, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Miasta: Gdańsk, Lublin, Poznań, Skórzewo i 2 inne miastaWiek: od 18 latSponsor: Summit Therapeutics Inc.
RekrutujeFaza III
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Miasta: Białystok, Gdańsk, Koszalin, Olsztyn i 5 innych miastWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels…
Miasta: Gdańsk, Gliwice, Lublin, Poznań i 2 inne miastaWiek: od 18 latSponsor: Pfizer Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Miasta: Bydgoszcz, Konin, Kraków, Opole i 4 inne miastaWiek: od 18 latSponsor: Celcuity Inc.
RekrutujeFaza III
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received…
Miasta: Biała Podlaska, Białystok, Brzozów, Gdańsk i 5 innych miastWiek: od 18 latSponsor: Janssen Cilag International
RekrutujeFaza II
Multicenter, open label study using molecularly determined targeted therapies in children 3-18 years of age with DIPG (diffuse intrinsic pontine glioma- DIPG)- DIPGen
Miasta: Katowice, WarszawaWiek: do 64 latSponsor: Instytut Pomnik Centrum Zdrowia Dziecka
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Miasta: Gdańsk, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC